
January 2, 2026
Regeneron Pharmaceuticals, Inc. announced it will release its financial and operating results for the fourth quarter and full year 2025 on January 30, 2026.
Read more →
December 22, 2025
Regeneron Pharmaceuticals, Inc. announced it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
Read more →
December 1, 2025
Regeneron Pharmaceuticals and Tessera Therapeutics have announced a global partnership to develop and commercialize TSRA-196, an investigational gene editing therapy aimed at treating alpha-1 antitrypsin deficiency (AATD).
Read more →
November 19, 2025
Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for treating patients with macular edema following retinal vein occlusion (RVO).
Read more →
November 8, 2025
Regeneron Pharmaceuticals has released results from two Phase 2 clinical trials that evaluated the antithrombotic effects of its investigational factor XI antibodies, REGN7508Cat and REGN9933A2, in patients undergoing total knee replacement surgery.
Read more →
November 3, 2025
Regeneron Pharmaceuticals, Inc. announced that members of its management team will participate in several upcoming investor conferences in November and December 2025.
Read more →
October 12, 2025
Nearly all children participating in a clinical trial for Regeneron Pharmaceuticals' investigational gene therapy DB-OTO experienced significant improvements in hearing, according to new data published in The New England Journal of Medicine and...
Read more →
September 30, 2025
Regeneron Pharmaceuticals, Inc. has announced it will release its financial and operating results for the third quarter of 2025 on October 28, prior to the opening of U.S. financial markets.
Read more →
September 26, 2025
Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Evkeeza (evinacumab-dgnb), an ANGPTL3 antibody, for use in children as young as one year old with homozygous familial hypercholesterolemia (HoFH).
Read more →
September 17, 2025
Regeneron Pharmaceuticals has released updated 26-week results from its Phase 2 COURAGE trial, which is studying the effects of combining semaglutide, a GLP-1 receptor agonist, with trevogrumab and garetosmab in patients with obesity.
Read more →
Sign-up for the Weekly Newsletter from Lohud Commercial.